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Abstract
Successful response in diethylcarbamazine (DEC) therapy in tropical pulmonary eosinophilia (TPE) is not universal with a 20–40% 
failure rates in chronic cases. Corticosteroids have been used in such patients. However, their role in management remains ill-de-
fined. A patient of TPE with incomplete clinical, haematological and physiological response to a standard 3 weeks DEC therapy 
received additional corticosteroids for the next two cycles, after which complete remission occurred. However, there was a 
relapse two months later with evidence of a chronic state requiring further treatment with corticosteroids with good response. 
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Introduction
Tropical pulmonary eosinophilia (TPE) is 
an eosinophilic lung disease associated with a 
hypersensitivity response to microfilariae of the 
parasites, Wuchereria bancrofti and Brugia ma-
layi [1]. It is fairly common in areas with filarial 
endemicity including regions of the Indian sub-
continent, South East Asia, South America and 
Africa. It occurs mostly in the age group of 15–40 
years with a male: female ratio of 4:1 [1].
The criteria for diagnosis of TPE include 
residence in an area endemic for filariasis, symp-
toms of recent onset of paroxysmal nocturnal 
cough with or without sputum, absolute blood 
eosinophil count of 2,000/µl or above, absence 
of circulating microfilaria in blood, and success-
ful clinical and haematological remission with 
diethylcarbamazine (DEC) therapy [1]. A standard 
treatment of DEC is 3–5 mg/kg body weight for 
3 weeks.
However, 20–40% failure rates have been 
reported with DEC therapy [2]. Corticosteroids 
have been used in such patients with variable 
success. Though usually considered an acute 
and treatable disease, a chronic state has also 
been described in TPE [2]. We report a patient 
with treatment failure with DEC who responded 
to corticosteroids but the disease was found to 
evolve into a chronic state on serial follow-up. 
An evolution from acute to a chronic state has 
not been documented in TPE.
Case report
A 45-year-old non-smoker female presented 
with a two-year history of paroxysmal dry co-
ugh and exertional breathlessness without any 
wheeze, fever and constitutional symptoms. Cli-
nical examination was not remarkable. Blood co-
unts showed a total white cell count of 17700/mm3 
with 32 % eosinophils and an eosinophil count 
(AEC) of 5800/mm3. Serum total IgE was 6240 
IU/ml. The chest radiograph (PA view) showed 
bilateral diffuse nodular shadows (Fig. 1). High 
resolution computed tomography (HRCT) scan 
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Figure 2. HRCT chest of the patient showing bilateral diffuse randomly 
distributed nodules
Figure 1. Chest radiograph (PA view) of the patient showing bilateral 
nodular shadows
showed bilateral diffuse, randomly scattered 
micro-nodular opacities without any lobar pre-
dilection (Fig. 2). Smears and cultures of spu-
tum obtained after induction were negative for 
pyogenes and acid fast bacilli. Blood test for 
micro-filarial antigen was negative but serology 
revealed positive titre of IgG anti-filarial antibo-
dies. Commercial kits were used for serological 
assays. Spirometry showed a moderately severe 
restrictive pattern. Details of blood investigations 
are shown in Table 1.
Serum precipitins and immunoglobulins E 
and G (IgE and IgG) against Aspergillus species, 
and skin prick test for type 1 hypersensitivity to 
Aspergillus antigens were negative. Fibreoptic 
bronchoscopy was not remarkable and a trans-
bronchial lung biopsy was non-contributory. 
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Bronchoalveolar lavage showed 81% eosinophils. 
A diagnosis of TPE was made on the basis of the 
established criteria [1, 2]. DEC therapy was star-
ted, 100mg thrice daily, for three weeks. 
There was only a partial relief in symptoms 
and the AEC was found to be increased (Table 
1). The chest radiograph showed no remarkable 
change while there was a slight worsening on spi-
rometry. Total lung capacity (TLC) estimation by 
closed circuit helium dilution confirmed restric-
tion. Single breath diffusion capacity for carbon 
monoxide (DLCO) was in the normal range. A 
second cycle of DEC was initiated but this time 
with added corticosteroids (20 mg prednisolone). 
The symptoms diminished considerably after 
three weeks’ treatment with a decline in peri-
pheral eosinophilia. Substantial improvement in 
FVC and FEV1 occurred though these were still 
reduced but the TLC recovered to the normal 
range. A second cycle of DEC plus prednisolone 
in the same doses for 3 weeks resulted in symp-
tomatic remission, disappearance of peripheral 
eosinophilia and normalization of lung function. 
The treatment was stopped.
The patient again developed exertional bre-
athlessness two months later with increased 
AEC. Spirometry and TLC measurements showed 
mild restriction and this time, the DLCO was also 
moderately reduced. HRCT chest showed bila-
teral diffuse, randomly scattered micro-nodular 
opacities, though less profuse than at baseline. 
In view of the radiological abnormality and a 
deteriorating lung function picture with diffusion 
impairment, a diagnosis of chronic lung disease 
due to TPE was made and the patient was advi-
sed to take long term corticosteroids, starting 
with 30mg per day of oral prednisolone that was 
gradually tapered over the next 3 months. There 
was a substantial improvement in symptoms and 
AEC (Table 1). Serum anti-filarial antibodies be-
came negative. Spirometry parameters and DLCO 
returned to the normal range but TLC remained 
below the normal limits, indicating persistent 
restrictive ventilator impairment. 
Discussion
TPE occurs as a hypersensitivity reaction 
to the microfilariae of the parasites, Wuchereria 
bancrofti and Brugia malayi [1]. It predominan-
tly affects the lungs. The respiratory symptoms 
include cough, breathlessness, wheezing and 
chest pain. Symptoms are usually more promi-
nent at night. Systemic symptoms include fever, 
weight loss, fatigue and malaise. Wheezes and 
crackles may be found on examination although 
20 per cent of patients may have no findings on 
examination [2]. Histopathologically, acute eosi-
nophilic and histiocytic infiltration, eosinophilic 
bronchopneumonia and eosinophilic abscesses 
characterize the initial phases of the disease with 
generally well-marked fibrous tissue formation 
between six months to two years in more chronic 
cases [3]. Fibrosis is usually interstitial but also 
be peribronchial and perivascular in distribution. 
It is slowly progressive. Later in the natural co-
urse, the lung is badly scarred with a restrictive 
pattern though never as crippling as in idiopa-
thic pulmonary fibrosis [2]. Patients who have 
frequent relapses or responded poorly to DEC 
are more likely to have impaired lung functions 
with progress to interstitial fibrosis. Spirometry 
is usually mixed restrictive-cum-obstructive with 
impaired diffusing capacity in chronic cases who 
may manifest mild hypoxemia due to ventilation
-perfusion mismatch. 
About 20 per cent of patients with TPE may 
have a normal chest radiograph. The main radio-
logical features include reticulo-nodular shadows 
more in the mid-to-lower zones and miliary mot-
tling resembling that seen in tuberculosis. HRCT 
scan often reveals miliary nodular shadows, 
bronchiectasis, air trapping and interstitial sha-
dows, and, rarely, lymphadenopathy, cavitation, 
consolidation or pleural effusions. Though arse-
nic compounds were used earlier, short courses 
of two or three weeks of DEC have remained the 
cornerstone of therapy for the last five decades [2]. 
Chronic or relapsing cases may have persistent 
or incomplete clinical and radiological resolution 
and may require such courses frequently. Role of 
corticosteroids remains undefined [4]. 
An incomplete response to DEC has been 
reported earlier in TPE [1, 3, 5, 6] and may occur 
due to resistance to therapy, inadequate duration 
of therapy or a transition into a chronic inflamma-
tory state. While resistance to DEC has not been 
documented, Vijayan et al. [6] provided evidence 
of a chronic inflammatory state on broncho-
alveolar lavage in patients with treatment failure 
with DEC. A mild eosinophilic inflammation of 
the lower respiratory tract was found with cells 
spontaneously releasing increased amounts of su-
peroxide anion and hydrogen peroxide. One-week 
treatment with prednisone significantly reduced 
the eosinophil inflammation and the release of 
oxidants [4]. In a recent review of natural history 
of TPE, Mullerpattan et al. [1] have also provi-
ded evidence of the development of a chronic 
lower airway and interstitial inflammatory state 
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followed by diffuse interstitial fibrosis. In such 
chronic patients, DEC may be ineffective in up 
to 20–40% cases.
Corticosteroids have potent anti-inflamma-
tory effects resulting from blocking of promoter 
sites of pro-inflammatory genes, recruiting of 
transcription factors to promoter sequences of 
genes coding for anti-inflammatory gene products 
and inhibition of the synthesis of almost all 
known cytokines [7, 8]. These drugs are also very 
effective in several eosinophilic lung diseases 
because of potent actions against the eosinophils, 
including promotion of eosinophil apoptosis and 
inhibition of degranulation of eosinophils [9, 10]. 
This explains their efficacy in TPE. It is also possi-
ble that the chronic interstitial inflammatory state 
represents a toxic response to DEC that responds 
to corticosteroids.
Antifilarial antibodies were not monitored 
during treatment except at the beginning and at 
the end of the treatment. The response in TPE is 
usually ascertained by symptoms and resolution 
of peripheral eosinophilia. In the present case, 
incomplete radiological resolution, relapse of 
peripheral eosinophilia and persistent restrictive 
abnormality of lung function after continued cor-
ticosteroid therapy suggested a transition into a 
chronic state. Thus, TPE may not be viewed as a 
benign and curable acute condition but one with 
a potential to progress to a chronic lung disease. 
This provides the rationale for corticosteroid 
therapy, especially in relapsing or chronic cases 
of TPE [2, 4]. The dose and duration of therapy 
in the long term management of TPE needs to be 
established. 
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